Immunohistochemistry biomarker TP53 expression predicts the survival of thymomas.

Background: Thymomas are rare malignancies. Thymectomy is the optimal therapy which could prolong the survival of patients. However, prognostic factors of thymomas are not clear.

Methods: Thymomas patients were enrolled from 2001 to 2016. Clinical and pathological prognostic factors of thymomas were evaluated by univariate and multivariate analyses.

Results: A total number of 98 patients was eligible for this study. All patients were received complete resection (CR). Diagnostic age [elder than the median 60 . younger than 60, hazard ratio (HR) =2.325, P=0.027], Masaoka stage (III I, HR =10.756, P<0.001; IV . I, HR =6.558, P=0.014), and diabetes mellitus (DM) (with without, HR =0.142, P=0.004) were independent prognostic factors for overall survival (OS). Immunohistochemistry (IHC) biomarker TP53 expression also influenced OS significantly (positive negative, HR =5.157, P=0.018). Furthermore, age (elder than 60 . younger than 60, HR =2.980, P=0.022) was independent prognostic factors for recurrence free survival (RFS).

Conclusions: We found that diagnostic age, clinical stages, DM, TP53 expression in IHC, and quality perioperative nursing are prognostic factors in thymomas.